Citi Pharma Ltd
Shariah compliantA sound balance sheet. No dividend last year, the price is in a downtrend and priced above its peers.
Working
- Debt is 28% of equity in the latest quarter.
- Profit up 22% on the same quarter last year.
- Operating margin 14% over the last twelve months, above its average of 12% over the last 3 years.
To watch
- P/E 17.0 against a sector median of 11.9.
- Short-term assets cover short-term bills 1.3 times in the latest quarter.
- Revenue up 4% on the same quarter last year.
Keep reading CPHL: business, price trend and value
How good the business is, where its support zone sits, what it may be worth, its health, dividends, peers and latest results open with a free account.
Latest results
Quarter: Jul–Sep 2026In the Jul–Sep 2026 quarter, CPHL's sales rose 4% to Rs 3.5bn, from Rs 3.4bn, and profit after tax rose 22% to Rs 248.8mn, from Rs 204.0mn (compared with Jul–Sep 2025).
Earnings per share were Rs 1.09, against Rs 0.89 a year earlier.
At Rs 62.35, CPHL trades at 15.7 times earnings.
- P/E ratio
- 15.7
- Dividend yield
- 0.0%
- Dividend payout
- 0%
- of earnings
- Return on equity
- 8%
- Net margin
- 6.0%
- last 12 months
- Debt to equity
- 0.28
CPHL quarterly results
Reported figures| Quarter | Sales | Profit after tax | Net margin | EPS | Dividend / share |
|---|---|---|---|---|---|
| Jul–Sep 2026 | Rs 3.5bn | Rs 248.8mn | 7.1% | Rs 1.09 | — |
| Apr–Jun 2026 | Rs 3.3bn | -Rs 92.7mn | -2.8% | -Rs 0.41 | — |
| Jan–Mar 2026 | Rs 3.1bn | Rs 275.0mn | 8.9% | Rs 1.21 | — |
| Oct–Dec 2025 | Rs 4.3bn | Rs 404.0mn | 9.3% | Rs 1.77 | — |
| Jul–Sep 2025 | Rs 3.4bn | Rs 204.0mn | 6.1% | Rs 0.89 | — |
| Apr–Jun 2025 | Rs 3.1bn | Rs 214.0mn | 7.0% | Rs 0.94 | Rs 3.50 |
| Jan–Mar 2025 | Rs 3.3bn | Rs 220.0mn | 6.6% | Rs 0.96 | — |
| Oct–Dec 2024 | Rs 3.5bn | Rs 257.0mn | 7.3% | Rs 1.12 | — |
CPHL annual results and dividends
Reported figures| Year | Sales | Profit after tax | EPS | Dividend / share |
|---|---|---|---|---|
| Year to Jun 2026 | Rs 14.1bn | Rs 790.3mn | Rs 3.46 | — |
| Year to Jun 2025 | Rs 13.2bn | Rs 892.0mn | Rs 3.90 | Rs 3.50 |
| Year to Jun 2024 | Rs 12.4bn | Rs 833.0mn | Rs 3.65 | Rs 3.25 |
| Year to Jun 2023 | Rs 12.4bn | Rs 658.0mn | Rs 2.88 | Rs 2.50 |
| Year to Jun 2022 | Rs 9.8bn | Rs 636.0mn | Rs 2.78 | — |
Balance sheet and price
Balance sheet as of Sep 2026- Total assets
- Rs 18.0bn
- Shareholders' equity
- Rs 11.1bn
- Cash & bank
- Rs 270.8mn
- Total debt
- Rs 3.1bn
- Current ratio
- 1.30
- 3-month high
- Rs 76.67
- 3-month low
- Rs 58.22
- 1-month change
- +1.2%
- 3-month change
- -15.1%
Read more about CPHL
Other pharmaceuticals companies
- ABOTAbbot Laboratories (Pakistan) LtdRs 924.15P/E 11.1
- AGPAGP LtdRs 149.85P/E 12.7
- BFBIOBF Biosciences LtdRs 123.20P/E 20.0
- CWHCCrestwell Healthcare LimitedRs 21.35
- FEROZFerozsons Laboratories LtdRs 337.68P/E 16.4
- GLAXOGlaxoSmithKline Pakistan LtdRs 315.00P/E 10.4
- HALEONHaleon Pakistan LtdRs 658.64P/E 12.7
- HINOONHighnoon Laboratories LtdRs 956.76P/E 12.1
- HPLHoehcst Pakistan LtdRs 4056.91P/E 10.4
- IBLHLIBL HealthCare LtdRs 39.86P/E 19.1
- LIVENLiven Pharma LimitedRs 31.47
- MACTERMacter International LtdRs 244.00P/E 15.3
CPHL: common questions
What is CPHL's share price?
Citi Pharma Ltd (CPHL) last closed at Rs 62.35 on the Pakistan Stock Exchange.
Does CPHL pay a dividend?
Citi Pharma Ltd reported no dividend for the year to Jun 2026.
What were CPHL's latest results?
In the Jul–Sep 2026 quarter, CPHL's sales rose 4% to Rs 3.5bn, from Rs 3.4bn, and profit after tax rose 22% to Rs 248.8mn, from Rs 204.0mn (compared with Jul–Sep 2025).
What is CPHL's P/E ratio?
At Rs 62.35, CPHL trades at 15.7 times its earnings.
Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.

